|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 13770 Noel Road |
Address2 | Suite 801889 |
City | Dallas |
State | TX |
Zip Code | 75280 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103626-12
|
||||||||
|
6. House ID# 428950001
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Molly Guthrie |
Date | 1/20/2021 11:28:15 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY2021, Labor, HHS and Education Appropriations bill specifically pertaining to funding of biomedical research, NBCCEDP and related cancer services
FY2021 funding for the DOD Breast Cancer Research Program
H.R.113, Consolidated Omnibus Appropriations Act for program funding related to research, screening and treatment for breast cancer
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.R.1730/S.741 - Cancer Drug Parity Act
H.R.2428/S.1632 - Access to Breast Cancer Diagnosis Act
H.R.2777/S.1936 - Protecting Access to Lifesaving Screenings Act
Efforts to reduce surprise medical billing
Public and private insurance adjustments and other policy changes due to the COVID-19 emergency, including those impacting the immunocompromised populations
Implementation of the Affordable Care Act
Policies related to co-pay assistance programs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.1370/S.562 - Breast Cancer Patient Equity Act
H.R.1946/S.518 - Lymphedema Treatment Act
H.R.2178/S.1374 - The Metastatic Breast Cancer Access to Care Act
H.R.8845/S.5051 - The Multi Cancer Early Detection Screening Coverage Act
H.R. 913/S.4742 Clinical Treatment Act
Medicare coverage policies for drugs and drug pricing
Medicare coverage policy for breast cancer treatments and services
Medicaid coverage and eligibility policies
Proposed waivers under Sections 1115 and 1332 of the Social Security Act
Proposed rule related to Securing Updated and Necessary Statutory Evaluations Timely
Proposed rule on Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency
Proposed rules on Notice of Benefit and Payment Parameters
Interim Final Rule on Most Favored Nation Policy
Coverage for telemedicine in Medicare
Radiation Oncology Alternative Payment Model
2021 Medicare Physician Fee Schedule Proposed Rule
2021 Medicare Hospital Outpatient Prospective Payment System Proposed Rule
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
FY21 National Defense Authorization Act (H.R.6395) - issues pertaining to the congressionally-directed medical research program, especially those relating the breast cancer
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Reauthorization of the Young Womens Breast Health Education and Awareness Requires Learning Young Act of 2009 by supporting the EARLY Act Reauthorization of 2020 (H.R.4078/S.2424)
H.R.1966/S.946-Henrietta Lacks Enhancing Cancer Research Act
H.R.6337-Health Equity and Accountability Act
H.R.6561/S.4440-Improving Social Determinants of Health Act
H.R.8558-Comprehensive Breast Reconstruction Act of 2020
Health disparities
Clinical trial continuation
Policies to increase clinical trial diversity
Executive Orders related to insurance coverage and drug pricing
Policies related to telehealth
Policies related to COVID-19 vaccination distribution
Comments on Draft Guidance for Industry on Developing Drugs for Treatment of Premenopausal Women with Breast Cancer
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |